Abstract. Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer. Previous studies have found that many microRNAs (miRNAs), including miRNA-126-3p, may play a critical role in the development of LUAD. However, no study of LUAD has researched the synergistic effects and co-targets of both miRNA-126-3p and miRNA-126-5p. The present study used real-time quantitative polymerase chain reaction (RT-qPCR) to explore the expression values of miRNA-126-3p and miRNA-126-5p in 101 LUAD and 101 normal lung tissues. Ten relevant microarray datasets were screened to further validate the expression levels of miRNA-126-3p and -5p in LUAD. Twelve prediction tools were employed to obtain potential targets of miRNA-126-3p and miRNA-126-5p. The results showed that both miRNA-126-3p and -5p were expressed significantly lower in LUAD. A significant positive correlation was also present between miRNA-126-3p and -5p expression in LUAD. In addition, lower expression of miRNA-126-3p and -5p was indicative of vascular invasion, lymph node metastasis (LNM), and a later tumor/node/metastasis (TNM) stage of LUAD. The authors obtained 167 targets of miRNA-126-3p and 212 targets of miRNA-126-5p; 44 targets were co-targets of both. Eight co-target genes (IGF2BP1, TRPM8, DUSP4, SOX11, PLOD2, LIN28A, LIN28B and SLC7A11) were initially identified as key genes in LUAD. The results of the present study indicated that the co-regulation of miRNA-126-3p and miRNA-126-5p plays a key role in the development of LUAD, which also suggests a fail-proof mode between miRNA-3p and miRNA-126-5p.
Introduction
Lung cancer (LC) is one of the world's most widespread cancers. More than 1.5 million people are diagnosed with LC every year (1, 2) . Lung adenocarcinoma (LUAD) is the most common histological subtype of LC (3, 4) . The 5-year survival rate for LUAD patients is less than 15%, as most are diagnosed at advanced stages (5) . Therefore, it is urgent to determine the molecular mechanism of LUAD and identify an effective method for early diagnosis and effective treatment.
MicroRNAs (miRNAs) are endogenous, non-coding, small RNAs. They control gene expression by combining with the messenger RNAs (mRNAs) of target genes, causing mRNA degradation or translation suppression (6, 7) . Numerous studies have demonstrated that the aberrant and disordered expression of miRNAs is involved in many malignant tumors, including LCs (8) (9) (10) (11) (12) .
Previous research has confirmed that miRNAs can be divided into three different forms, as follows: primary (pri-) miRNA, precursor (pre-)miRNA and mature miRNA. The mature miRNAs designated as miRNA-3p and miRNA-5p are derived from the 3' or 5' arms, respectively, of their pre-miRNAs (13) . Theoretically, therefore, all pre-miRNAs can produce two types of mature miRNAs. Previous research assumed that only one mature miRNA took part in regulating target mRNAs; the other was thought to be a byproduct, and it was regarded as functionally irrelevant (14) . Increasingly, however, recent investigations have confirmed that both miRNA-3p and miRNA-5p originate from one pre-miRNA and can degrade various target mRNAs (15) . Studies also have found a correlation and synergistic effects between miRNA-3p and -5p produced by the same pre-miRNA (16) . These findings suggest that miRNA-3p and -5p both function during biological processes, implying that they may co-regulate target genes in various diseases.
miRNA-126-3p and miRNA-126-5p (miRNA-126-3p/5p) are both derived from pre-miRNA-126, which is located on human chromosome 9. miRNA-126-3p and -5p have been identified as essential biological factors in the development of certain malignancies (17) . Regarding LC, studies with small sample sizes have confirmed that miRNA-126-3p is downregulated in non-small cell lung cancers (NSCLCs), including LUAD (18) . Nevertheless, previous studies concerning LC have mainly focused on miRNA-126-3p; no research has demonstrated a relationship between miRNA-126-5p and LC. It is also worth noting that LUAD research has not investigated or clarified whether a correlation or synergistic effects between miRNA-126-3p and -5p exist. Based on previous research, the authors predicted that both miRNA-126-3p and -5p may be less expressed in LUAD and may co-regulate key target genes of LUAD.
The present study aimed to explore the clinical utility and investigate the correlation and synergistic effects of miRNA-126-3p and miRNA-126-3p in LUAD. A total of 202 tissues (101 LUAD tissues and 101 adjacent normal lung tissues) were collected. Real-time quantitative polymerase chain reaction (RT-qPCR) was performed to explore the respective expression values of miRNA-126-3p and -5p in the 202 tissues. A large sample size from the Gene Expression Omnibus (GEO) database was obtained so that a meta-analysis could be performed with the RT-qPCR data from the present study to further identify miRNA-126-3p and -5p expression in LUAD. In addition, 12 prediction software programs were employed to obtain the target genes of miRNA-126-3p and -5p. Then, bioinformatic analysis was conducted to identify the potential molecular mechanisms of miRNA-126-3p and -5p in LUAD. This is the first study to investigate the co-regulation of miRNA-125-3p and -5p in LUAD. It is hoped that the present study may demonstrate the molecular function and synergistic effects of miRNA-126-3p and miRNA-126-3p. The obtained research findings may reveal the importance of these miRNAs in LUAD diagnosis and treatment.
Materials and methods
Clinical LUAD sample collection. Based on a previous study (19) , 202 formalin-fixed, paraffin-embedded (FFPE) tissues were collected at the First Affiliated Hospital of Guangxi Medical University (Nanning, China). Of these 202 FFPE tissues, 101 were LUAD tissues, while the remaining 101 tissues were paired adjacent normal lung tissues. The research protocol for this study has been ratified by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. Consent from all patients was obtained at the time of the sample collection.
RT-qPCR.
RT-qPCR is a sensitive technique for quantifying specific RNA targets. RNA was removed from the FFPE sample tissues using a miRNeasy FFPE kit (Qiagen, Venlo, The Netherlands) as previously described (20, 21) . A NanoDrop 2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used to ensure the purity and concentration of the extracted RNA from the FFPE tissues. The specific primers of miRNA-126-3p and miRNA-126-5p were provided by TaqMan MicroRNA Assays (4427975-000468; Applied Biosystems, Life Technologies Europe B.V., Gent, Belgium). The reverse primers were included in TaqMan MicroRNA Reverse Transcription kit (4366596; Applied Biosystems, Life Technologies Europe B.V) (22) . RNU6B was used as the internal control. The forward primer sequences of RNU6B were 5'-CTC GCT TCG GCA GCA CA-3' and the reverse primer sequences were 5'-AAC GCT TCA CGA ATT TGC GT-3'. The sequences of miRNA-126-3p were 5'-UCG UAC CGU GAG UAA UAA UGC G-3' and the sequences of miRNA-126-5p were 5'-CAU UAU UAC UUU UGG UAC GCG-3'. The thermocycling conditions were as follows: denaturation at 95˚C for 10 min, followed by 40 cycles of 95˚C for 15 sec and 60˚C for 60 sec. The RT-qPCR was analyzed with Applied Biosystems PCR 7900 (Applied Biosystems; Thermo Fisher Scientific, Inc.) to detect miRNA expression values. Relative expression values were calculated using the 2 -∆Cq method (23) .
GEO data extraction. GEO (https://www.ncbi.nlm.nih. gov/gds/) is the largest fully disclosed high-throughput molecular abundance database; it is mainly used to store gene expression data. All microarray datasets related to LUAD were filtered out and downloaded from the GEO database. The microarray dataset selection criteria were as follows: i) the samples had to be human tissue; ii) the dataset had to contain LUAD and non-cancerous lung tissue groups; iii) both the LUAD and non-cancerous lung tissue groups had to include at least two samples; and iv) expression values of miRNA-126-3p or -5p had to be available. A receiver operating characteristic (ROC) curve based on the RT-qPCR data was applied to estimate the respective distinguishing impact of miRNA-126-3p and -5p on LUAD from non-cancerous tissues. Binary logistic regression and ROC curve analyses were performed for evaluating the combined distinguishing value of miRNA-126-3p and -5p (24, 25) . Stata statistical software (version 12.0; Stata Corp., College Station, TX, USA) was used to perform a meta-analysis of the GEO data; the results were assessed using the standard mean difference (SMD). The heterogeneity of the GEO data was assessed by I 2 statistics and a Q test. An I 2 >50% or a P-value <0.05 was deemed to indicate huge heterogeneity. A summary ROC (SROC) analysis based on the selected microarray datasets as well as the results from the present study was performed to determine the potential distinguishing effect of miRNA-126-3p and -5p on LUAD.
Predicting miRNA-126-3p and-5p targets. Twelve target gene prediction software programs (TargetScan, miRWalk, Microt4, miRDB, miRanda, miRBridge, miRMap, miRNAMap, PITA, PicTar2, RNA22 and RNAhybrid) (http://zmf.umm. uni-heidelberg.de/apps/zmf/mirwalk2/miRretsys-self.html) were run to obtain the miRNA-126-3p and -5p target genes. Only genes that appeared in more than two of the prediction programs were selected as candidate targets. At the same time, an R function package was used to screen all the overexpressed genes in LUAD from The Cancer Genome Atlas (TCGA) database (https://cancergenome.nih.gov/). Fold change (FC) was used to assess the level of gene expression in the TCGA data, and genes were deemed to be overexpressed if the FC >2. Then, the predicted target genes were overlapped with the overexpressed genes to obtain the miRNA-126-3p and -5p target genes in LUAD.
Bioinformatic analysis. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) version 6.8 (https://david.ncifcrf.gov/) was employed for Gene Ontology (GO) analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to analyze the function of the above-identified genes in LUAD. A protein-protein interaction (PPI) network based on the target genes of miRNA-126-3p and -5p was established using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (http://www.string-db.org/) and Cytoscape version 3.4.0 (26) was used to determine the correlation between each target. Table I . Expression of miRNA-126-3p and miRNA-126-5p in LUAD according to RT-qPCR data.
Results

Expression of miRNA-126-3p and miRNA-126-5p in LUAD tissues according to RT-qPCR
miRNA-126-3p
miRNA-126-5p AUC of 0.689 (P<0.001; Fig. 1D ). The combined ROC curve of miRNA-126-3p and -5p in LUAD tissues revealed an AUC of 0.821 (P<0.001; Fig. 1E ).
Association between miRNA-126-3p and miRNA-126-5p and the clinicopathological parameters of the LUAD samples.
The RT-qPCR analysis determined that miRNA-126-3p levels differed significantly according to TNM stage, while miRNA-126-5p levels differed significantly in regards to vascular invasion, lymph node metastasis (LNM) and TNM stage (Table I) demonstrated that the AUC was 0.625 (P=0.032; Fig. 2H ). No significant difference was observed between miRNA-126-3p
and -5p and other clinicopathological features (all P>0.05; Table I ). (Table II) (27) (28) (29) (30) (31) (32) (33) (34) (35) . A random-effects model was used because major heterogeneity existed (I 2 =91.0%, P<0.001). The meta-analysis demonstrated that miRNA-126-3p expression was significantly lower in LUAD tissues than it was in normal lung tissues [SMD=-2.063, 95% confidence interval [CI]: -2.829 to -1.298, P<0.001; Fig. 3A] .
Eight microarray datasets (GSE14936, GSE19945, GSE25508, GSE29248, GSE47525, GSE48414, GSE51853 and GSE74190) contained data concerning expression of miRNA-126-5p in 305 LUAD and 139 normal lung tissues. As major heterogeneity also existed in the meta-analysis of miRNA-126-5p (I 2 =87.5%, P<0.001), a random-effects Figure 4 . Sensitivity and specificity of the microarray datasets and the present study. Sensitivity and specificity of the 10 relevant microarray datasets and the present study according to the expression of (A) miRNA-126-3p and (B) miR-126-5p. CI, confidence interval.
model was again performed. The results showed that miRNA-126-5p also exhibited significantly low expression in LUAD tissues (SMD=-1.152, 95% CI, -1.804 to -0.499, P=0.001; Fig. 3B ).
Next, the sensitivity and specificity of each microarray dataset and the present study were extracted (Fig. 4) . The SROC curves of miRNA-126-3p and miRNA-126-5p, respectively, for LUAD tissues were performed using the GEO data and the present study's RT-qPCR data. The SROC of miRNA-126-3p showed an AUC of 0.97 (Fig. 5A) , while the SROC of miRNA-126-5p showed an AUC of 0.90 (Fig. 5B) .
Funnel plots were employed to assess the publication bias of the two meta-analyses ( Fig. 6A and B) . The results of Begg's test (P=0.533 and P=0.533) and Egger's test (P= 0.592, P= 0.307) showed no statistically significant differences for either meta-analysis. Sensitivity analysis for these two meta-analyses revealed that significantly lower expression of miRNA-126-3p and miRNA-126-5p existed regardless of which microarray datasets were removed ( Fig. 6C and D) .
Correlation analysis between miRNA-126-3p and miRNA-126-5p.
A Pearson correlation analysis was performed based on the GEO data to assess the correlation between miRNA-126-3p and miRNA-126-5p expression. Of the eight microarray datasets, six showed significant positive correlations (r=0.671-0.991, all P<0.05; Fig. 7 ), one suggested a tendency toward a positive correlation (r=0.486; P=0.678) and one suggested a trend toward a negative correlation (r=-0.557, P=0.251).
Bioinformatic analysis based on the target genes of miRNA-126-3p and miRNA-126-5p
Prediction of the target genes. Twelve online prediction tools were employed for acquiring the potential targets of miRNA-126-3p and -5p, respectively. Initially, 2,248 genes and 1,905 genes were separately collected as the target genes of miRNA-126-3p and -5p. In addition, 5,271 upregulated genes in LUAD tissues were also obtained from the TCGA database. After the upregulated genes were overlapped with the 2,248 targets of miRNA-126-3p and the 1,905 targets of miRNA-126-5p, 167 genes and 212 genes, respectively, were identified as the targets of miRNA-126-3p and -5p in LUAD. Combining the 167 targets of miRNA-126-3p and 212 targets of miRNA-126-5p produced 335 total target genes; 44 genes were co-targets of both miRNA-126-3p and miRNA-126-5p (Fig. 8) .
GO analysis, KEGG pathways and PPI. Based on these 335 target genes, GO and KEGG pathway analyses were conducted to determine their molecular biological functions in LUAD. The results of the GO analysis indicated that the targets were mainly enriched in cell-cell signaling of biological processes (BPs), which are integral to the plasma membrane of cell components (CCs) and channel activity of molecular functions (MFs) ( Table III) . The KEGG pathway analysis showed that target genes were significantly enriched in neuroactive ligand-receptor interaction (Table Ⅳ) . In addition, a PPI network of these 335 target genes was performed (Fig. 9) . Eight crucial co-target genes (IGF2BP1, TRPM8, DUSP4, SOX11, PLOD2, LIN28A, LIN28B and SLC7A11) were selected for further analysis. All were significantly highly expressed in LUAD (all P<0.001; Fig. 10 ).
Discussion
In recent years, the effect of microRNAs (miRNAs) on the pathogenesis of cancers has been well investigated and clarified. However, even as the investigation of miRNAs has matured and their functions have become clearer, the co-function of miRNA-3p and -5p is rarely mentioned. The present study verified the co-downregulation of the expression of miRNA-126-3p and miRNA-126-5p in lung adenocarcinoma (LUAD) tissues using real-time quantitative polymerase chain reaction (RT-qPCR) and the GEO database. Bioinformatic analysis based on the obtained target genes of miRNA-126-3p and -5p was performed to clarify their co-regulation in LUAD. The function of miRNA-126-3p has been articulated in previous research. miRNA-126-3p levels have been shown to be downregulated in various malignancies including colorectal, esophageal, oral, liver, breast, thyroid and renal cancers (36) (37) (38) (39) (40) (41) (42) . In contrast, investigations of miRNA-126-5p in malignant tumors have been rare and limited. Several studies have reported that miRNA-126-5p is expressed at a lower level in colorectal and breast cancers (43, 44) . As for lung cancer (LC), several studies have reported that miRNA-126-3p expression is downregulated in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), suggesting that it is an LC suppressor (45, 46) . The targets of miRNA-126-3p have also been described in previous studies. Liu and colleagues pointed out that miRNA-126-3p could inhibit the growth of LC cell lines by targeting vascular endothelial growth factor (VEGF) (47) . Moreover, Song et al demonstrated that miRNA-126-3p targeted PIK3R2 and affected the PTEN/PI3K/AKT signaling pathway to suppress the growth of an NSCLC cell line (48) . As for the role and effect of miRNA-126-5p in LC, available literature is scarce.
All previous studies concerning miRNA-126 in LC investigated miRNA-126-3p and ignored the function of miRNA-126-5p. To the best of our knowledge, no previous study has explored the co-function of miRNA-126-3p and -5p in LC. The present study first concentrated on the co-function and co-targets of miRNA-126-3p and -5p in LUAD. A total of 202 tissues and 11 microarray datasets were collected to identify the co-expression of miRNA-126-3p and -5p in LUAD. Bioinformatic analysis based on the potential target genes was performed in the hopes of identifying the co-regulation and synergistic effects of miRNA-126-3p and -5p in LUAD.
Both miRNA-126-3p and miRNA-126-5p are derived from precursor miRNA-126 and are associated with angiogenesis and cell proliferation in malignancies. The present study confirmed that both miRNA-126-3p and -5p have lower expression in LUAD tissues, indicating that both may be LUAD tumor suppressors. In addition, expression levels of miRNA-126-3p and -5p were significantly downregulated in late stage LUAD. The miRNA-126-5p expression levels were significantly lower in samples with vascular invasion and LNM, suggesting that miRNA-126-3p and -5p were related to the development, invasion, and metastasis of LUAD. Lower expression of miRNA-126-3p and -5p suggested a worse prognosis of LUAD.
In addition, correlation analysis showed a positive correlation between miRNA-126-3p and -5p expression, meaning that in LUAD, miRNA-126-5p levels decreased as miRNA-126-3p decreased. Thus, miRNA-126-3p and -5p are not expressed independently in LUAD; they are expressed consistently. Analysis of miRNA-126-3p and -5p levels also showed that although these two miRNAs are expressed consistently, the level of miRNA-126-5p was usually lower than that of miRNA-126-3p in the same LUAD tissue sample. This observation conforms to the rule of mature miRNA expression: When miRNA-3p and -5p are developed from the same precursor, one of them is often more highly expressed than the other (14) . Previous research improperly assumed that the lower-expressed miRNA was functionally irrelevant, while the higher-expressed one played a leading role in biological processes (13, 14) . In fact, additional research has demonstrated the important function of both miRNA-3p and -5p (49) . The present study confirmed the significantly lower expression of both miRNA-126-3p and -5p in LUAD and demonstrated their association with TNM stage, invasion and metastasis; it also confirmed that both of them perform important functions. Their consistent expression may indicate a synergistic effect in LUAD.
The target predictions further demonstrated the synergistic effects of miRNA-126-3p and -5p. Combining the 167 target genes of miRNA-126-3p with the 212 targets of miRNA-126-5p revealed that these two miRNAs share 44 co-targets. In other words, 26% (44/167) of miRNA-126-3p targets and 20% (44/212) of miRNA-126-5p targets were co-targets of both.
This high target overlap provides credible evidence for their co-regulation in LUAD. The combined 335 targets were mainly enriched in neuroactive ligand-receptor interaction and ECM-receptor interaction of the KEGG pathway. However, when the 167 miRNA-126-3p targets and 212 miRNA-126-5p targets were separately considered to explore the KEGG pathway, the results also showed that the targets were mainly enriched in neuroactive ligand-receptor interaction and ECM-receptor interaction. Thus, miRNA-126-3p and -5p may influence LUAD development together via a similar signaling pathway.
More importantly, many of these co-targets have been identified as key genes in LC development. IGF2BP1 has been proven to be a target gene of miRNA-491-5p. miRNA-491-5p can downregulate IGF2BP1 to suppress the growth of NSCLC (50) . TRPM8 was found to contribute to an invasive phenotype in LC (51). Furthermore, DUSP4 was shown to function as a suppressor and can inhibit the growth of EGFR-mutant LUAD (52) . SOX11 was found to exhibit significantly higher expression in LC and is associated with a prognosis of neuroendocrine tumors of the lung (53) . PLOD2 was proven to be regulated by the PI3K/AKT-FOXA1 axis to promote the metastasis of LC, and its high expression is indicative of a worse prognosis of LUAD (54) . miRNA-98 may suppress the expression of LIN28A to decrease the invasion and metastasis of LC cells (55) , while LIN28B expression is high in tumor-initiating cells from NSCLC and functions in the tumorigenesis of lung cancer cells (56) . The overexpression of SLC7A11 was shown to be associated with poor prognosis of LC (57) . According to TCGA data, all these co-targets play critical roles and are overexpressed in LUAD. miRNA-126-3p and -5p may directly target these key genes at the same time to co-regulate the development of LUAD. Downregulation of the expression of miRNA-126-3p and -5p reduces their combination with these targets, which decreases the degradation of these target genes and causes them to be highly expressed in LUAD. It will be meaningful to deeply research these potential targets and further validate that they are the downstream targets of miRNA-126-3p and -5p in LUAD. However, the core point of this study was to demonstrate the co-regulation as well as the synergistic effects of miRNA-125-3p and -5p in LUAD, while elucidating the downstream target genes is a secondary viewpoint of our study. Thus, we completed a preliminary identification of these potential targets. Further and intensive investigation is needed to validate them in the future.
It is worth mentioning that the co-function of miRNA-3p and -5p has only recently begun to be recognized and investigated. In fact, many miRNA-3p and -5p pairs have been found to co-regulate the same malignant tumors (49) . The present study demonstrated the co-regulation of miRNA-126-3p and -5p in LUAD. The present results and the PPI network provide clear evidence of the existence of the synergistic effects between miRNA-126-3p and -5p in LUAD. The co-regulation of miRNA-126-3p and -5p may be a fail-proof mode of the regulation of miRNAs in LUAD or other malignancies, which can ensure that if either miRNA-126-3p or -5p is disabled by transcriptional inhibition or mutation, the associated biological function may still proceed stably and normally (58) . In the regulation of a malignant tumor, this fail-proof mode may also exist between pairings other than miRNA-3p and -5p or even between miRNAs from two different families.
In conclusion, the present study verified the co-downregulation of the expression of miRNA-126-3p and -5p in LUAD tissues and discovered the existence of co-target genes between miRNA-126-3p and -5p, many of which have been confirmed to be closely related to the proliferation, invasion, metastasis and poor prognosis of LC. These results indicate that the co-regulation of miRNA-126-3p and -5p plays a significant role in the development of LUAD, which also implies a fail-proof mode between miRNA-3p and -5p. While miRNA-126-5p is by no means equivalent to miRNA-126-3p, the two miRNAs possess vital associations and valuable clinical significance in LUAD and various other malignancies.
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